Health Canada provided conditional approval of Ibrance (palbociclib) for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer as initial endocrine-based therapy for metastatic disease. The Health Canada approval of Ibrance is based on the final results of the phase II PALOMA-1/TRIO 18 trial (n=165), which studied...
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
